Allogeneic stem cell transplantation from haploidentical donor using an unmanipulated graft and post-transplantation cyclophosphamide (PT-Cy) is growing. Haploidentical transplantation with PT-Cy showed a major activity in Hodgkin lymphoma (HL), reducing the relapse incidence. The most important predictive factor of survival and toxicity was disease status before transplantation, which was better in patients with well controlled disease. We included 198 HL in complete (CR) or partial remission (PR) before transplantation. Sixty-five patients were transplanted from haploidentical donor and 133 from a HLA identical donor (both sibling and unrelated donors). Survival analysis was defined according to the EBMT criteria. Survival curves were generated by using Kaplan-Meier method and differences between groups were compared by the log rank test or by the log rank test for trend when appropriated. The PFS, OS, and RI were significantly better in patients in CR compared to PR (55% vs 29% p = 0.001, 74% vs 55% p = 0.03, 27% vs 55% p < 0.001, respectively). The 2-year PFS was significantly better for HAPLO than HLA-id (63% vs 37%, p = 0.03), without difference in OS. The 1-year NRM was not different. The 2-year relapse incidence (RI) was lower in the HAPLO group (24% vs 44%, p = 0.008). Patients in CR receiving haplo HSCT showed higher 2-year PFS and lower 2-year RI than those allografted with HLA-id donor (75% vs 47%, p < 0.001 and 11% vs 34%, p < 0.001, respectively). In multivariate analysis, donor type and disease status before transplantation were independent predictors of PFS as well as they predict the risk of relapse. Disease status at transplantation and age were independently associated to OS. Nonetheless this is a retrospective study, limiting the wide applicability of results, data from this analysis suggest that HLA mismatch can induce a strong graft versus lymphoma effect leading to an enhanced PFS.

中文翻译：

---

化学敏感霍奇金淋巴瘤患者的单倍相关供体与HLA相同供体的比较

来自单倍体供体的同种异体干细胞移植正在使用未处理的移植物和移植后的环磷酰胺（PT-Cy）进行种植。单倍体PT-Cy移植在霍奇金淋巴瘤（HL）中显示出主要活性，从而降低了复发率。存活和毒性的最重要的预测因素是移植前的疾病状态，在控制良好的患者中更好。我们在移植前包括了198例完全（CR）或部分缓解（PR）的HL。65名患者从单倍体供体移植，133例从HLA相同供体（同胞和无关亲戚供体）移植。生存分析是根据EBMT标准定义的。使用Kaplan-Meier方法产生生存曲线，并通过对数秩检验或对数秩检验比较组之间的差异（如果适用）。与PR相比，CR患者的PFS，OS和RI显着更好（分别为55％vs 29％p = 0.001、74％vs 55％p = 0.03、27％vs 55％p <0.001）。HAPLO的2年PFS明显好于HLA-id（63％比37％，p = 0.03），而OS没有差异。1年NRM并无不同。HAPLO组的2年复发率（RI）较低（24％对44％，p = 0.008）。接受单倍体HSCT的CR患者的2年PFS和2年RI低于同种HLA-id供者（分别为75％vs 47％，p <0.001和11％vs 34％，p <0.001）。在多元分析中，移植前的供体类型和疾病状况是PFS的独立预测因子，并且可以预测复发的风险。移植时的疾病状况和年龄与OS独立相关。尽管如此，这是一项回顾性研究，限制了结果的广泛适用性，该分析的数据表明HLA错配可以诱导强烈的移植物抗淋巴瘤效应，从而导致PFS增强。